Business Wire

AZ-BLUE-YONDER

29.3.2024 13:14:28 CET | Business Wire | Press release

Share
Blue Yonder Announces Binding Agreement To Acquire One Network Enterprises for Approximately $839 Million To Create Multi-Enterprise Supply Chain Ecosystem

Blue Yonder, a leader in digital supply chain transformations, continues its forward momentum to revolutionize the supply chain and has today announced the signing of an agreement to acquire One Network Enterprises (One Network) for approximately $839 million, subject to adjustments. One Network, provider of the Digital Supply Chain Network™, is known for its autonomous and resilience services and is a leading global provider of intelligent control towers. Upon completion, Blue Yonder will be well positioned to serve customers’ needs across planning, execution, commerce, and networks.

“Supply chains have become more complex, and as more and more companies reduce risk by diversifying sourcing of products globally, there is an increased demand for the sharing of information and resources across the whole value chain. This, along with increased disruptions and geopolitical risks, have put the pressure on organizations to build more resilient and robust supply chains,” said Duncan Angove, CEO, Blue Yonder. “Combined with One Network’s capabilities, Blue Yonder will establish itself as a leading supply chain solutions company that can offer a unified, end-to-end supply chain ecosystem that is resilient enough to withstand today’s challenges, and synthesized with innovative, future-focused technologies.”

The combination of One Network’s Digital Supply Chain Network™ and Blue Yonder’s supply chain capabilities create an ecosystem that:

  • Offers real-time, multi-enterprise optimization, orchestration, and collaboration both inside and outside an organization – across multi-tiers from customers to carriers to suppliers to the suppliers’ suppliers.
  • Allows customers to move from the order planning phase to the fulfillment phase instantly, eliminating the time gap that normally occurs from entering the order to beginning the physical fulfillment. Customers can also tap into a more complete and actionable data set across the multi-enterprise ecosystem by setting up alerts, benefiting from automation, and leveraging generative artificial intelligence (AI).
  • Provides real-time visibility across the supply chain, allowing customers to take immediate action via upstream and downstream collaboration.
  • Unifies disparate data silos, enabling a holistic, executive-level view into the entire supply chain – resulting in the ability to automatically optimize and execute through prescriptive real-time decision-making technology.

In addition, carriers and suppliers will be able to leverage a range of services designed specifically for their needs, including: advanced shipment scheduling management, telematics tracking and predictive insights, real-time visibility to on-time delivery trends (by site, lane, carrier, distribution center), and the ability to manage by exception.

“Supply chains continue to be fragmented and overwhelmed with disruptions. What’s needed is a unified platform that enables multi-tier orchestration, planning, and collaboration that accelerates processes with autonomous and semi-autonomous decision-making and execution across trading partners. This is the next step to creating a resilient and collaborative supply chain,” said Greg Brady, chairman and founder, One Network. “Blue Yonder offers the most complete portfolio in the industry, spanning from planning to execution. Coupled with our network and multi-enterprise, multi-tier platform, we’re poised to form a backbone of this new supply chain of the future.”

By tapping into One Network’s revolutionary platform and multi-party network, leveraged by over 150,000 trading partners, Blue Yonder’s customers will benefit from an ecosystem that:

  • Accelerates end-to-end decision-making, with increased visibility into materials, resources, loads, routes, and capacity.
  • Offers real-time insights and predictions, enabling the ability to take action across the supply chain ecosystem, leading to fewer disruptions and a more resilient supply chain.
  • Shares data seamlessly across the entire multi-tier supply chain, including suppliers and carriers, allowing for streamlined insights into potential disruptions and the ability to mitigate risk.
  • Improves supplier and carrier collaboration processes – from order creation through scheduling and fulfillment – from days to minutes, removing inaccuracies, reducing time, and decreasing cost.
  • Enables the journey to autonomous supply chain management through Smart Prescriptions™, adaptive flows, and interactive visualizations, powered by proprietary AI technology.

The closing of the transaction is subject to the satisfaction of customary conditions precedent in transactions of this type, including necessary regulatory approvals, and is expected to occur in Q2 or Q3 2024. This deal is indicative of Blue Yonder's momentum in the supply chain management space, and when completed, will mark approximately $1 billion in M&A investments covering three acquisitions since Q4 2023. This announcement comes on the heels of Blue Yonder’s acquisition of flexis, offering factory planning, sequencing, and slotting capabilities, and Doddle, offering returns management and reverse logistics solutions.

About One Network Enterprises

One Network Enterprises (ONE) is a leading global provider of intelligent control towers and the Digital Supply Chain Network™. Its solutions give supply chain managers and executives end-to-end visibility and control with one data model and one truth, from raw material to last-mile delivery. Powered by NEO, One Network’s machine learning and intelligent agent technology, it enables seamless planning and execution, across inbound supply, outbound order fulfillment, and logistics, matching demand with available supply in real-time. Lead your industry by providing the highest service levels and product quality at the lowest possible cost. Visit: www.onenetwork.com

About Blue Yonder

Blue Yonder is a world leader in digital supply chain transformation. Global retailers, manufacturers, and logistics providers leverage Blue Yonder to optimize their supply chains from planning through fulfillment, delivery, and returns. Blue Yonder’s AI-embedded, interoperable supply chain solutions are connected end-to-end via a unified platform and data cloud, enabling business to collaborate in real time across functions, which supports more agile decision-making, improved customer satisfaction, profitable growth, and more resilient, sustainable supply chains. Blue Yonder – Fulfill your Potential blueyonder.com

“Blue Yonder” is a trademark or registered trademark of Blue Yonder Group, Inc. Any trade, product or service name referenced in this document using the name “Blue Yonder” is a trademark and/or property of Blue Yonder Group, Inc. All other company and product names may be trademarks, registered trademarks, or service marks of the companies with which they are associated.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240328293246/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye